- Kincell Bio appoints Mark R. Bamforth as CEO, effective immediately.
- The company aims to enhance its cell therapy CDMO capabilities under Bamforth’s leadership.

Kincell Bio, a cell therapy development and manufacturing organisation, has announced the appointment of Mark R. Bamforth as Chief Executive Officer (CEO). Effective immediately, Bamforth brings decades of experience in the biopharmaceutical industry to the role, having founded and led three successful CDMOs: Arranta Bio, Brammer Bio, and Gallus Bio.
Mark has served as Chair of the Board at Kincell Bio since May 2024. His new position will focus on advancing the company’s mission to provide tailored, high-quality solutions for innovators in the rapidly growing cell therapy sector. “I look forward to building on the solid foundation that Bruce has established and working more deeply with him and the talented team at Kincell Bio to expand our cell therapy CDMO business,” said Bamforth.
Bruce Thompson, PhD, will continue as Chief Technology Officer (CTO), leading the process and analytical development team. Dr. Thompson’s expertise spans allogeneic therapies, stem cell products, and iPSC-derived modalities, and he will focus on technical innovation and partnerships to address scale and performance challenges in cell therapy.
Kincell Bio’s comprehensive offerings include process and analytical development, early and late-stage cGMP manufacturing, and tailored solutions for biotech and pharmaceutical companies. With a strengthened leadership team, the company is poised to empower clients in delivering therapies to market efficiently.